O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham | Strategic Alliance Partners

Mezigdomide, tazemetostat, and dexamethasone demonstrated early efficacy signals in patients with refractory multiple myeloma.

Amitkumar Mehta, MD, discusses FDA-approved treatment options for patients with diffuse large B-cell lymphoma and follicular lymphoma in later lines.

akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.

Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Arnab Basu, MD, MPH, FACP, discusses the phase 2 MRD Gate RCC trial of molecular residual disease–guided adjuvant therapy in in renal cell carcinoma.

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

Luciano J. Costa, MD, PhD, discussed extended follow-up data from the trial and explained how the results may affect frontline treatment decisions in multiple myeloma.

A groundbreaking discovery by Markus Bredel, MD, PhD, and colleagues not only marks a significant milestone in our understanding of diffuse gliomas but also paves the way for improved predictions of disease outcomes and the development of targeted treatment approaches.

Francine Walton, MPH, shares how her mother has shaped her perspective on the cancer journey, including the importance of hope and resilience in the face of adversity.

The addition of ofranergene obadenovec to paclitaxel failed to significantly improve survival outcomes compared with paclitaxel alone in patients with platinum-resistant ovarian cancer.

Luciano J. Costa, MD, PhD, discusses the background of the phase 2 MASTER trial in newly diagnosed multiple myeloma.

The University of Alabama at Birmingham, in partnership with the Alabama Department of Public Health and the American Cancer Society, recently launched Wipe Out Cervical Cancer ­— a statewide action plan to eliminate cervical cancer as a public health problem in Alabama.

Susan Bal, MD, discusses questions remaining regarding sequencing of treatments in later lines for patients with relapsed/refractory multiple myeloma.

The O’Neal Comprehensive Cancer Center at UAB is pleased to announce that Rebecca Arend, M.D., MSPH, will join Drs. Narendra Wajapeyee and Suzanne Lapi as Co-Leader of the O’Neal Experimental Therapeutics Research Program.

Ahmed Elkhanany, MD discusses unmet needs in patients with estrogen receptor–positive breast cancer who progress on frontline therapy, treatment considerations for these patients, and how FES PET imaging may benefit this population.

Susan Bal, MD, discusses the toxicity profile of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, according to findings from a phase 1 trial.

Susan Bal, MD, discusses updated safety and efficacy data from the dose-escalation and dose-expansion portions of phase 1 trial of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in patients with relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.

Ahmed Elkhanany, MD, discusses biological drivers of disease in patients with estrogen receptor–positive breast cancer who have disease progression shortly after initiating first-line therapy, as well as the importance of performing comprehensive genetic testing in these patients to determine subsequent treatment approaches. 

Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.

Susan Bal, MD, discusses the clinical implications for the use of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.

Susan Bal, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Maya Khalil, MD, discusses the use of first-line durvalumab plus tremelimumab in patients with non–small cell lung cancer enrolled in the phase 3 POSEIDON trial, and sheds light on histologies and mutations that are associated with increased benefit with this regimen.

Devika Das, MD, MSHQS, discusses the activity and tolerability of lurbinectedin and topotecan as second-line regimens in extensive-stage small cell lung cancer.

Susan Bal, MD, discusses the evolution of CAR T-cell therapy in multiple myeloma.

Devika Das, MD, MSHQS,discusses updated data on the use of immunotherapy and platinum-based chemotherapy regimens in extensive-stage small cell lung cancer.

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.